Blue Jet Healthcare Q1 FY26: Revenue jumps 118% YoY

Key takeaway from the June-quarter update

Blue Jet Healthcare has shared a detailed snapshot of its June-quarter performance, alongside an investor communication schedule that puts focus on near-term commentary. The company has also flagged that its board meeting to consider the audited financial results is scheduled for August 03, 2026. On the same day, an analyst and investor conference call is scheduled at 5:30 PM IST.

The financial data shared for the June quarter shows a sharp year-on-year jump in revenue and profit, but a sequential moderation in margins and earnings. Revenue rose to ₹354.76 crore, while net income came in at ₹91.17 crore. QoQ comparisons in the data are against the immediately preceding March quarter.

What Blue Jet Healthcare reported for the quarter

Total revenue for the June quarter stood at ₹354.76 crore, compared with ₹234.67 crore in the March quarter, a 4.20% increase on the QoQ comparison provided. Against the year-ago June quarter, revenue was ₹162.90 crore, translating into 117.78% YoY growth.

Profitability also improved sharply on a year-on-year basis. Net income rose to ₹91.17 crore versus ₹37.78 crore in the year-ago period, a YoY increase of 141.34%. Net income before taxes was ₹122.86 crore, compared with ₹49.47 crore in the year-ago quarter.

On a sequential basis, net income and pre-tax profit declined. Net income fell 17.19% QoQ from ₹64.34 crore, while net income before taxes declined 16.54% QoQ from ₹87.15 crore, as per the comparison fields provided.

Cost line items and operating performance

Operating income was reported at ₹115.30 crore for the quarter versus ₹64.81 crore in the March quarter. The table also shows operating income of ₹40.78 crore in the year-ago quarter.

Total operating expense increased to ₹239.46 crore from ₹169.86 crore in the March quarter and ₹122.12 crore in the year-ago quarter. Depreciation and amortization was ₹5.70 crore, compared with ₹6.46 crore in the March quarter and ₹3.48 crore in the year-ago quarter.

Selling, general and administrative expenses were ₹17.43 crore, compared with ₹18.48 crore in the March quarter and ₹14.78 crore in the year-ago quarter. Other operating expenses were reported at ₹33.44 crore for the June quarter, versus ₹42.72 crore in the March quarter.

EPS and what it indicates

Diluted normalized EPS for the quarter was ₹5.26, compared with ₹3.71 in the March quarter and ₹2.18 in the year-ago quarter. The QoQ comparison in the data indicates a 17.07% decline, despite the quarter’s higher revenue.

The same dataset shows a strong YoY expansion in EPS of 141.28%, aligning with the sharp improvement in net income versus the year-ago period.

Earnings call on August 3: who will speak and when

Blue Jet Healthcare Limited has announced its Q1FY27 earnings call for August 3, 2026, to discuss its unaudited standalone financial results for the quarter ended June 30, 2026. The company will host an analyst and investor conference call on Monday, August 03, 2026, at 5:30 PM IST.

The management participants listed for the discussion are Shiven Arora (Managing Director), V.K. Singh (Chief Operating Officer), Ganesh Karuppannan (Chief Financial Officer), and Sanjay Sinha (Deputy Chief Financial Officer). The dial-in numbers provided are +91 22 6280 1107 and +91 22 7115 8008.

Management commentary and operating drivers cited

In the company’s discussion of quarterly drivers, it attributed growth to higher sales in the PI and API product category. It also reported a gross margin of about 48.4% to 48.5% for the quarter and noted that this was lower than the prior quarter due to inventory-related impact and product mix.

Managing Director Shiven Arora indicated that gross margin is anticipated to stabilize around 53%, factoring in what was described as a one-time inventory effect.

Liquidity and capital spending disclosed

The disclosures state that the company held ₹270 crore in cash and treasury instruments. Capital expenditure in the first quarter was reported at ₹28 crore.

These data points can influence how investors assess flexibility for capacity, compliance, and working capital needs, especially in quarters where product mix and inventory movements affect gross margin.

What recent volatility looked like: the Q3 FY26 reference

The company also referenced a weaker quarter earlier in the cycle. Blue Jet Healthcare’s Q3 FY26 revenue dropped 40% YoY to ₹192.4 crore (from ₹318.4 crore), and EBITDA declined 62% to about ₹46.2 crore.

That decline was attributed to channel destocking and supply chain realignment. The inclusion of this context is relevant because it shows that sales and margins can be sensitive to channel inventory adjustments and distribution changes.

Summary table: June quarter versus March and year-ago

Market snapshot and the number investors will watch

The quick data shared alongside the results includes a current market price (CMP) of ₹580.3. The same panel lists the previous quarter revenue at ₹234.7 crore and previous quarter PAT at ₹64.3 crore.

With the board meeting and earnings call scheduled for August 03, 2026, the market’s immediate focus is likely to remain on the company’s explanations for margin movement, changes in product mix, and any update on normalization of gross margin.

Analysis: why the June-quarter mix and margins matter

The June-quarter set of numbers presents two signals at once. First, the year-on-year comparison shows a sizable scale-up in revenue and profit. Second, the sequential decline in PAT and the cited drop in gross margin highlight that the earnings trajectory can vary meaningfully with inventory levels and product mix.

The company’s stated expectation of gross margin stabilising around 53% frames an explicit metric for investors to monitor in subsequent updates. Separately, the Q3 FY26 destocking and supply-chain realignment reference provides a reminder that channel conditions can affect reported growth and profitability even when underlying demand is stable.

Conclusion

Blue Jet Healthcare’s June-quarter results show revenue of ₹354.76 crore and PAT of ₹91.17 crore, with strong YoY growth but a QoQ dip in earnings. The next key event is August 03, 2026, when the board considers audited results and management addresses investors on the scheduled 5:30 PM IST call.